ProKidney (PROK) Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Which has better valuation & earnings, AUPH or PROK?

ProKidney has lower revenue, but higher earnings than Aurinia Pharmaceuticals. ProKidney is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$247.30M	4.47	-$78.02M	$0.28	29.20
ProKidney	$306K	823.57	-$35.47M	-$0.60	-1.44

Do analysts rate AUPH or PROK?

Aurinia Pharmaceuticals presently has a consensus price target of $11.50, indicating a potential upside of 40.67%. ProKidney has a consensus price target of $4.50, indicating a potential upside of 422.65%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ProKidney	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media refer more to AUPH or PROK?

In the previous week, Aurinia Pharmaceuticals had 6 more articles in the media than ProKidney. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 2 mentions for ProKidney. ProKidney's average media sentiment score of 1.83 beat Aurinia Pharmaceuticals' score of 1.44 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is AUPH or PROK more profitable?

ProKidney has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. ProKidney's return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%
ProKidney	N/A	N/A	-10.24%

Do insiders & institutionals believe in AUPH or PROK?

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 41.5% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more risk & volatility, AUPH or PROK?

Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Does the MarketBeat Community believe in AUPH or PROK?

Aurinia Pharmaceuticals received 569 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 53.33% of users gave ProKidney an outperform vote.

Company	Underperform	Outperform
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%
ProKidney	Outperform Votes 8 53.33%	Underperform Votes 7 46.67%

Summary

ProKidney beats Aurinia Pharmaceuticals on 10 of the 18 factors compared between the two stocks.